See the DrugPatentWatch profile for Obinutuzumab
How much does obinutuzumab (Gazyva) cost in the US?
Pricing for obinutuzumab is usually reported as a mix of (1) the manufacturer’s list price and (2) what patients actually pay after insurance, discounts, and patient-assistance programs. Public “cash” prices can be very high, so the out-of-pocket cost depends heavily on coverage and where the drug is administered.
If you tell me your country (and whether you have commercial insurance, Medicare, or Medicaid), I can narrow the answer to the right pricing references and typical patient cost patterns.
What affects a patient’s out-of-pocket cost for obinutuzumab?
Out-of-pocket costs can change based on:
- Insurance type and formulary placement (in or out of network, prior authorization requirements)
- Whether the claim is processed under the medical benefit (common for IV infusions) versus pharmacy benefit
- Deductibles and coinsurance, plus the plan’s annual out-of-pocket maximum
- Infusion setting billing (hospital vs outpatient clinic), since administration charges are often separate from the drug itself
- Patient assistance programs or copay cards (eligibility can exclude certain government-insured patients)
Does obinutuzumab have generics or biosimilars that lower the price?
Obinutuzumab is a biologic. Lower-cost biosimilars (when available) can reduce cost, but availability and uptake depend on the country’s approval status and payer contracting. If you share your location, I can check whether a biosimilar is currently expected or available there and what that typically means for pricing.
What dosing schedule impacts total drug cost?
Total spend depends on the number of infusions in the course and patient body measurements used in dosing. The cost generally rises with the total number of doses and with any dose reductions or regimen changes. If you share the indication (for example, CLL or follicular lymphoma) and whether you’re looking at a first course vs subsequent maintenance, I can help estimate the drug quantity drivers that move total cost.
Are there financial assistance options for obinutuzumab?
Many high-cost oncology biologics have manufacturer or partner programs that may provide:
- Copay support for commercially insured patients
- Free drug or reduced-cost options for eligible uninsured/underinsured patients
- Help coordinating prior authorization and billing paperwork
Eligibility rules vary by country, insurance status, and income.
What if you’re comparing obinutuzumab cost vs alternatives?
Patients and clinicians often compare total cost and coverage between similar treatments in the same disease area (for example, other anti-CD20 antibodies). The “cost difference” can come from:
- Drug acquisition price
- Infusion regimen length and dosing frequency
- Side-effect profiles that affect supportive care needs
- How payers place each option on their formulary
If you name the specific alternative(s) you’re considering and your location, I can frame the cost comparison around what typically matters for payers.
---
If you answer these 3 questions, I can give you a much more precise cost estimate:
1) What country are you in?
2) Do you want list price, insurance-based estimate, or out-of-pocket cost?
3) What is the indication (e.g., CLL, follicular lymphoma) and are you looking at the initial course or maintenance?